BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics

Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15.  You can find the session topics below.

Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche

The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications for small business grantees or biotech companies who wish to collaborate with federal grantees.

A Landmark Case: The Aftermath of Myriad

This session will provide an update on the status of the case and the arguments that have been made by the various amicus groups, with particular emphasis on the US Government’s brief. We will also explore the impact of “gene patents” on up-and-coming technologies, especially whole genome/whole exome testing.

The Business Case for International Humanitarian Approaches to IP Management and Collaborations

Guest Speaker:

Erik Iverson, Associate General Counsel, Global Health, Gates Foundation

 

Best Practices in Research Collaborations: Joint Inventorship Pitfalls and Ethical Issues in Joint Representation

Don Ware of Foley Hoag will lead a discussion of pitfalls that may arise from prosecuting joint inventions conceived in the course of research collaborations among multiple institutions, including companies, universities and hospitals. Irene Pleasure, Associate General Counsel and Director of Patent Law at Genentech, will provide the in-house perspective on managing patent issues in research collaborations. David Hricik, Professor of Law at Mercer University School of Law and co-author of the treatises Patent Ethics – Prosecution (2009) and Patent Ethics – Litigation (2010), will address the professional responsibilities of patent attorneys involved in the prosecution of jointly-owned patent applications.

How to Stay in the Frying Pan and Out of the Fire: Hot Topics in Ethics for In-House IP Attorneys

Professor David Hricik and Barbara Fiacco of Foley Hoag will present on developments in ethics law for in-house IP counsel, including law firm conflict issues, how to protect the attorney-client privilege, ethical dilemmas created by 21st century social media, in-house counsel ethical pitfalls, and recent developments in IP malpractice law. The game-show format of this panel will be thought-provoking and fun, and will encourage audience participation. CLE Ethics credit is being requested.

Learn How to Navigate IP Landscape in Emerging Markets

BIO members have indicated a strong desire to hear about challenges and key developments in emerging markets such as Korea, China, Brazil and India. Specific challenges, lay of the land, how to negotiate better in these markets.

Double Patenting

This panel will include new developments on the Boehringer Ingelheim Federal Circuit Case, collaboration of multiple parties/how to avoid double patenting rejections and possible coverage of the Sun v. Lilly case.

The Next Chapter: Biosimilars Beyond the Health Care Reform Act

Will Policy Issues Slow the Pace of Implementation? Will the FDA Look to Europe for Guidance on Antibody Biosimilars? Emerging Markets, Emerging Strategies? The panel will cover recent developments in biosimilar, including policy issues based on move to repeal healthcare reform, the recent FDA public hearing on biosimilars, further debate on the meaning of exclusivity, the necessity of clinical trials, the possibility of interchangeability, and developments in Europe with respect to antibody biosimilars.

Advertisement

2011 BIO International Convention Super Sessions

2011 BIO International Convention Super Sessions Focus on State of the Industry

C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends

WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take place June 27-30, 2011 at the Walter E. Washington Convention Center in Washington D.C.

“The last few years have presented significant economic challenges for emerging biotech companies trying to raise investment capital, which has had a global impact on the industry. Despite recent positive signs, it is still a tough market,” said BIO CEO and President Jim Greenwood. “These Super Sessions feature high-level speakers sharing their long-term outlook on the industry, and suggested strategies for successfully rebounding from the financial challenges and moving innovation forward to help heal, fuel and feed the world.”

Super Sessions include:

Ernst & Young’s 25th Annual Biotechnology Industry Report

Ernst & Young will present highlights from its 25th annual industry report. The session will discuss implications for biotech companies as they face a more uncertain future in the current business climate. As always, Ernst & Young will also summarize the sector’s performance using key metrics – financial performance, financing, deals and pipeline productivity.

Sponsored by: Ernst & Young 
Tuesday, June 28, Time: 10:00 am – 11:30 am
Confirmed Speakers: Glen Giovannetti, Partner and Global Biotech Leader, Ernst & Young LLP; Gautam Jaggi, Senior Manager and Editor, Beyond Borders and Progressions, Ernst & Young LLP

Burrill State-of-the-Industry Report
This presentation will look back over 25 years and describe some of the critical events that have shaped the industry into the global enterprise it is today and discuss what companies will need to do in order to remain competitive in a world being influenced by a tougher financial climate, rapidly evolving technology, globalization and new emerging markets.

Sponsored by: Burrill & Company
Tuesday, June 28, Time: 2:00 pm – 3:30 pm
Confirmed Speaker: G. Steven Burrill, Chief Executive Officer, Burrill & Company  

It Takes a Village– The Biotechnology Innovation Ecosystem

This session will detail the roles, relationships and interplay among government research labs, universities, and large and small biotechnology firms in the continuum from basic research to FDA-approved products and ultimately to the patient.

Sponsored by: Eli Lilly and Company
Tuesday, June 28, Time: 3:45 pm – 5:15 pm
Confirmed Speaker: John Lechleiter, Ph.D., Chairman, President & Chief Executive Officer, Eli Lilly & Company

Emerging Markets: The Future of Growth for Biologics?

This panel will bring together leading business executives with senior government officials to talk about how Emerging Markets are shaping business thinking and what impact they will have on the future of the biotech sector.

Sponsored by: Merck
Wednesday June 29, Time: 10:00 – 11:30 am
Confirmed Speaker: Richard T. Clark, Chairman, Merck

Campbell Alliance 2011 Dealmakers’ Intentions

Campbell Alliance and BIO present updated findings from two unique forward-looking measures of deal-making in the industry – the Campbell Alliance Dealmakers’ Intentions Survey and the BIO One-on-One Partnering Forecast.  New analysis in 2011 will include year-over-year trends and the first assessment of the predictive value of these instruments.

Sponsored by: Campbell Alliance
Wednesday June 29, Time: 2:00 – 3:30 pm
Speakers to be announced. 

Worldview 2011: Scientific American’s Regional Bio-Innovation Scorecard

Worldview 2011 will feature the third annual Scientific American’s Regional Bio-Innovation Scorecard, a review of individual country programs and policies aimed at growing local innovative biotechnology sectors. 

Wednesday June 29, Time: 3:45 – 5:15 pm
Confirmed Speaker: Fareed Zakaria, CNN host, Editor-at-Large of TIME Magazine, Washington Post columnist, former Editor, Newsweek International

The 2011 BIO International Convention is expected to draw more than 15,000 industry leaders from 49 states and 65 countries.  This year, the Convention program will feature more than 125 sessions in 16 tracks.  In addition, this year’s BIO Exhibition will cover an estimated 180,000 net sq. ft. and host more than 1,700 exhibitors.

The BIO International Convention also includes the BIO Business Forum, which offers attendees an unparalleled opportunity for large and small biotech companies to gather in one place, at one time to engage in partnering discussions. The ability to schedule up to 80 one-on-one meetings within just a few short days with biotech leaders from around the world enables companies to maximize their ROI for the registration and travel investment for this event. In 2010, the BIO Business Forum hosted more than 17,000 partnering meetings with more than 2,000 companies participating.

The BIO International Convention helps to support the association’s programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.  For additional attendee and exhibitor information, please visit http://convention.bio.org.

For detailed descriptions and a full program, please visit http://convention.bio.org.

Advance media registration for the 2011 BIO International Convention is now open and will be available online through June 17, 2011. To register in advance, please visit http://convention.bio.org/media.

BIO’s Intellectual Property Counsels’ Committee Spring Conference and Meeting: Seattle

Over the past eight years, BIO’s semiannual IP Counsels Committee Conference has become a popular and growing event among our members’ IP and legal professionals. Our upcoming 2011 Spring IPCC Conference in Seattle, WA on April 13-15 will be an excellent opportunity for IP professionals to hear, listen, and learn about current and projected topics related to biotechnology IP.

We invite you to join us in an informal, fun and informative setting to meet fellow in-house legal and IP professionals, to make new acquaintances, to reconnect with old friends in the industry, and to take home a wealth of information – and maybe some new ideas.

To Register

Session Titles:

1.  Whose Rights are They, Anyway?  Implications from and a Discussion on Stanford v. Roche

2.  A Landmark Case: The Aftermath of Myriad

3.  Best Practices in Research Collaborations: Joint Inventorship Pitfalls and Ethical Issues in Joint Representation

4.  How to Stay in the Frying Pan and Out of the Fire: Hot Topics in Ethics for In-House IP Attorneys

5.  Emerging Markets

6.  Double Patenting

7.  Biosimilars